Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

INOVIO PHARMACEUTICALS, INC.

(INO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Thinking about buying stock in Adagio Therapeutics, 180 Life Sciences, InMed Pharmaceuticals, Beyondspring, or Inovio Pharmaceuticals?

11/29/2021 | 08:31am EST

NEW YORK, Nov. 29, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ADGI, ATNF, INM, BYSI, and INO.

To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link.

(Note: You may have to copy this link into your browser then press the [ENTER] key.)

InvestorsObserver's PriceWatch Alerts are based on our proprietary scoring methodology. Each stock is evaluated based on short-term technical, long-term technical and fundamental factors. Each of those scores is then combined into an overall score that determines a stock's overall suitability for investment.

InvestorsObserver provides patented technology to some of the biggest names on Wall Street and creates world-class investing tools for the self-directed investor on Main Street. We have a wide range of tools to help investors make smarter decisions when investing in stocks or options.

Cision
View original content to download multimedia:https://www.prnewswire.com/news-releases/thinking-about-buying-stock-in-adagio-therapeutics-180-life-sciences-inmed-pharmaceuticals-beyondspring-or-inovio-pharmaceuticals-301432846.html

SOURCE InvestorsObserver


ę PRNewswire 2021
All news about INOVIO PHARMACEUTICALS, INC.
01/21BofA Securities Upgrades Inovio Pharmaceuticals to Neutral From Underperform, Adjusts P..
MT
2021Jefferies Assumes Inovio Pharmaceuticals at Hold, $6 Price Target
MT
2021INOVIO Highlights Key Updates on Phase 3 Program for VGX-3100, its DNA-based Immunother..
PR
2021INOVIO Updates on Phase 3 Program for VGX-3100 for HPV-Associated Cervical High-Grade S..
CI
2021Inovio Pharmaceuticals Evaluates Two COVID-19 Vaccine Candidates Against Omicron Varian..
MT
2021INOVIO Announces Strategy to Address Omicron (B.1.1.529) and Future SARS-CoV-2 Variants
PR
2021Thinking about buying stock in Adagio Therapeutics, 180 Life Sciences, InMed Pharmaceut..
PR
2021Novavax developing vaccine that targets new COVID-19 variant
RE
2021Novavax developing vaccine that targets new COVID-19 variant
RE
2021Inovio Pharmaceuticals Begins Dosing in Phase 1 Trial of Ebola Vaccine
MT
More news
Analyst Recommendations on INOVIO PHARMACEUTICALS, INC.
More recommendations